false 0001642380 0001642380 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

Insight Molecular Diagnostics Inc.

(Exact name of Registrant as specified in its charter)

 

California   1-37648   27-1041563
(State or other jurisdiction
of incorporation)
  (Commission
File No.)
  (IRS Employer
Identification No.)

 

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip code)

 

(615) 255-8880

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, no par value   IMDX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 17, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as underwriter (the “Underwriter”), relating to an underwritten public offering (the “Offering”) of (i) 8,296,429 shares (the “Shares”) of the Company’s common stock, no par value per share (“Common Stock”), and (ii) pre-funded warrants to purchase up to 275,000 shares of Common Stock (the “Pre-Funded Warrants”), at a public offering price of $1.75 per Share and $1.7499 per Pre-Funded Warrant (which represents the per share offering price for the Shares less the $0.0001 per share exercise price for each Pre-Funded Warrant). Pursuant to the Underwriting Agreement, the Company also granted the Underwriter a 30-day option to purchase up to an additional 1,285,714 shares of the Common Stock at the public offering price, net of underwriting discounts and commissions. The Offering is expected to close on or about November 18, 2026 (the “Closing Date”), subject to the satisfaction or waiver of customary closing conditions.

 

All of the securities in the Offering are being sold by the Company.

 

Aggregate gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting underwriting discounts and commissions and estimated expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

 

The Underwriting Agreement additionally contains customary representations, warranties and covenants made by the Company, including an agreement by the Company that the Company may not dispose of, or announce the offering of, or submit or file any registration statement, prospectus or prospectus supplement in respect of, any shares or securities convertible into or exchangeable for Common Stock until 90 days following the date of the Underwriting Agreement, subject to certain exceptions.

 

The Underwriting Agreement also provides for customary indemnification by each of the Company and the Underwriters for losses or damages arising out of or in connection with the Offering, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions.

 

Each Pre-Funded Warrant has an exercise price of $0.0001 per share of Common Stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. A holder may not exercise any portion of its Pre-Funded Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after exercise.

 

The Offering is being made pursuant to the Company’s registration statement on Form S-3 (File No. 333-281159) filed with the Securities and Exchange Commission (the “SEC”) on August 1, 2024, and declared effective on August 7, 2024, a base prospectus dated August 7, 2024, a preliminary prospectus supplement, dated November 16, 2026 and a prospectus supplement, dated November 17, 2026 and filed with the SEC on November 18, 2026.

 

The foregoing descriptions of the material terms of the Underwriting Agreement and Pre-Funded Warrants do not purport to be complete and are each qualified in their entirety by reference to the Underwriting Agreement and form of Pre-Funded Warrant, respectively, which are filed as Exhibit 1.1 and Exhibit 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

 

The legal opinion, including the related consent, of Haynes and Boone, LLP relating to the issuance and sale of the Shares is filed as Exhibit 5.1 hereto.

 

Item 8.01 Other Events.

 

On November 16, 2026, the Company issued a press release announcing the launch of the Offering. On November 17, 2026, the Company issued a press release announcing the pricing of the Offering. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
1.1*   Underwriting Agreement, dated November 17, 2026, by and between Insight Molecular Diagnostics Inc. and Lake Street Capital Markets, LLC.
4.1   Form of Pre-Funded Warrant.
5.1   Opinion of Haynes and Boone, LLP.
23.1   Consent of Haynes and Boone, LLP (included in Exhibit 5.1).
99.1   Press Release, dated November 16, 2026.
99.2   Press Release, dated November 17, 2026.
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

* Certain schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will provide a copy of such omitted materials to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INSIGHT MOLECULAR DIAGNOSTICS INC.
     
Date: November 18, 2026 By: /s/ Peter Hong
  Name: Peter Hong
  Title: Vice President, General Counsel